


































Supplementary Figure 1. Joinpoint regression plots for the prevalence⁺ of cigarette use, by age and sex, for adult participants in the US NHIS 2015-2025

Age Groups	Males and Females	APC% (95% CI)	Males	APC% (95% CI)	Females	APC% (95% CI)
≥18 years		2015-2023 -4.3 (-5.6 to -3.2)		2015-2023 -4.1 (-5.0 to -3.1)		2015-2023 -4.7 (-6.2 to -3.3)
18-24 years		2015-2019 -14.8 (-18.3 to -11.1)		2015-2019 -13.3 (-17.8 to -8.6)		2015-2019 -10.1 (-14.7 to 0.5)
25-34 years		2015-2019 -3.3 (-6.0 to 2.0)		2015-2019 -3.7 (-5.9 to -0.1)		2015-2019 -2.8 (-7.8 to 15.7)
35-54 years		2019-2023 -12.6 (-17.2 to -9.9)		2019-2023 -11.2 (-14.7 to -9.1)		2019-2023 -14.6 (-29.1 to -9.9)
35-54 years		2015-2023 -3.2 (-4.4 to -1.9)		2015-2023 -2.2 (-3.5 to -0.9)		2015-2023 -4.3 (-6.4 to -2.1)
≥55 years		2015-2023 -1.2 (-2.0 to -0.4)		2015-2023 -1.7 (-3.5 to 0.3)		2015-2017 3.6 (-2.0 to 10.1)
						2017-2023 -1.7 (-7.9 to 1.3)

[†]Prevalence estimates based on weighted data
Note: **Bold** indicates significant at the $p < 0.05$ level.

Supplementary Figure 2. Joinpoint regression plots for the prevalence[†] of other combustible tobacco product use^{*}, by age and sex, for adult participants in the US NHIS 2015-2025
















Age Groups	Males and Females	APC% (95% CI)	Males	APC% (95% CI)	Females	APC% (95% CI)
≥18 years		2015-2023 -0.6 (-2.2 to 1.0)		2015-2023 -0.7 (-2.8 to 1.4)		2015-2023 -0.5 (-2.5 to 1.6)
18-24 years		2015-2020 -4.3 (-10.5 to 12.9) 2020-2023 -13.9 (-28.1 to -5.3)		2015-2023 -6.6 (-11.1 to -1.9)		2015-2021 -4.0 (-12.4 to 22.5) 2021-2023 -32.2 (-48.5 to -9.4)
25-34 years		2015-2023 1.3 (-1.2 to 4.0)		2015-2019 0.9 (-1.9 to 3.9)		2015-2023 2.2 (-0.5 to 5.0)
35-54 years		2015-2023 1.2 (-1.3 to 3.7)		2015-2023 0.5 (-1.2 to 2.3)		2015-2023 3.8 (0.3 to 7.5)
≥55 years		2015-2023 -0.5 (-3.0 to 2.1)		2015-2023 -0.8 (-3.2 to 1.7)		2015-2023 0.4 (-6.5 to 7.9)

[†]Prevalence estimates based on weighted data

*Other combustible tobacco use includes cigars, pipe tobacco, and hookah tobacco











Note: **Bold** indicates significant at the $p < 0.05$ level.

Supplementary Figure 3. Joinpoint regression plots for the prevalence⁺ of electronic cigarette use, by age and sex, for adult participants in the US NHIS 2015-2025

Age Groups	Males and Females	APC% (95% CI)	Males	APC% (95% CI)	Females	APC% (95% CI)
≥18 years		2015-2017 -9.2 (-18.8 to 5.1) 2017-2023 14.5 (11.1 to 23.3)		2015-2017 -9.0 (-19.9 to 9.4) 2017-2023 13.2 (7.1 to 31.8)		2015-2018 -3.0 (-17.5 to 7.4) 2018-2023 18.9 (13.2 to 35.1)
18-24 years		2015-2023 16.3 (9.2 to 24.0)		2015-2023 11.5 (5.3 to 17.9)		2015-2023 26.0 (19.8 to 32.6)
25-34 years		2015-2023 14.7 (7.6 to 22.3)		2015-2023 13.3 (6.9 to 20.1)		2015-2023 17.2 (12.7 to 21.9)
35-54 years		2015-2017 -20.9 (-38.3 to 14.3) 2017-2023 14.9 (-14.0 to 57.3)		2015-2017 -18.0 (-34.8 to 11.5) 2017-2023 13.8 (-5.5 to 47.8)		2015-2017 -24.5 (-38.3 to 3.7) 2017-2023 16.2 (7.8 to 45.6)
≥55 years		2015-2020 -8.1 (-28.5 to 1.6) 2020-2023 16.8 (-2.7 to 50.6)		2015-2020 -9.6 (-28.2 to -1.3) 2020-2023 18.9 (0.3 to 53.8)		2015-2018 -15.7 (-28.0 to -6.2) 2018-2023 8.8 (3.4 to 20.4)

[†]Prevalence estimates based on weighted data
Note: **Bold** indicates significant at the $p < 0.05$ level.

Supplementary Figure 4. Joinpoint regression plots for the prevalence⁺ of oral tobacco product use^{*}, by age and sex^{**}, for adult participants in the US NHIS 2015-2025

Age Groups	Males and Females	APC% (95% CI)	Males	APC% (95% CI)
≥18 years		2015-2023 -0.9 (-3.9 to 2.3)		2015-2023 -1.1 (-3.7 to 1.6)
18-24 years		2015-2023 -11.2 (-16.1 to -5.8)		2015-2023 -10.8 (-15.5 to -5.6)
25-34 years		2015-2023 -0.1 (-2.6 to 3.0)		2015-2023 -0.7 (-3.5 to 2.2)
35-54 years		2015-2023 0.3 (-4.4 to 5.1)		2015-2023 0.1 (-3.7 to 4.1)
≥55 years		2015-2023 2.3 (-0.7 to 5.5)		2015-2023 2.4 (0.2 to 4.7)

[†]Prevalence estimates based on weighted data

*Oral tobacco product use includes chewing tobacco, moist snuff, and nicotine pouches

**The number of exclusive oral tobacco users among females was too low to reliably report prevalence estimates

Note: **Bold** indicates significant at the $p < 0.05$ level.

Sample size, n	1043	1014	766	740	810	670	691	618	599
Prevalence, %	18.3%	19.8%	18.1%	18.9%	17.9%	16.4%	16.8%	16.5%	16.0%
95% CI	(17.0-19.6)	(18.3-21.3)	(16.6-19.5)	(17.3-20.4)	(16.5-19.3)	(14.9-17.8)	(15.5-18.1)	(15.1-18.0)	(14.7-17.4)
• ≥55 years									
Sample size, n	913	997	757	765	894	831	730	732	787
Prevalence, %	13.5%	14.7%	13.0%	13.7%	13.6%	12.6%	11.9%	12.5%	12.6%
95% CI	(12.2-14.7)	(13.5-15.9)	(11.8-14.1)	(12.6-14.8)	(12.6-14.6)	(11.6-13.7)	(10.9-12.9)	(11.5-13.5)	(11.7-13.5)
Females									
• ≥18 years									
Sample size, n	2666	2645	1949	1815	2090	1748	1652	1494	1498
Prevalence, %	13.6%	13.5%	12.2%	12.0%	12.7%	11.0%	10.1%	10.0%	9.2%
95% CI	(12.9-14.2)	(12.8-14.3)	(11.4-13.0)	(11.2-12.7)	(12.0-13.4)	(10.3-11.6)	(9.5-10.7)	(9.4-10.7)	(8.6-9.8)
• 18-24 years									
Sample size, n	188	195	113	75	93	47	47	28	26
Prevalence, %	11.0%	11.5%	8.8%	7.3%	8.2%	5.5%	4.5%	3.3%	2.5%
95% CI	(8.8-13.2)	(9.4-13.7)	(6.8-10.8)	(5.1-9.5)	(6.3-10.1)	(3.7-7.4)	(3.0-5.9)	(1.9-4.7)	(1.5-3.6)
• 25-34 years									
Sample size, n	516	469	329	316	342	215	219	169	163
Prevalence, %	15.0%	13.9%	13.0%	14.0%	14.4%	10.5%	8.6%	8.0%	7.5%
95% CI	(13.3-16.7)	(12.2-15.5)	(11.4-14.7)	(12.1-15.9)	(12.6-16.1)	(8.9-12.0)	(7.3-9.8)	(6.6-9.6)	(6.2-8.7)
• 35-54 years									
Sample size, n	1075	1010	703	663	791	621	590	527	528
Prevalence, %	17.5%	17.0%	14.0%	14.4%	15.8%	13.5%	12.7%	12.9%	11.9%
95% CI	(16.2-18.8)	(15.6-18.4)	(12.7-15.3)	(13.0-15.7)	(14.5-17.1)	(12.2-14.7)	(11.6-13.8)	(11.7-14.1)	(10.7-13.0)
• ≥55 years									
Sample size, n	887	971	804	761	864	865	797	770	781
Prevalence, %	10.2%	11.0%	11.2%	10.4%	10.8%	10.7%	10.2%	10.5%	9.8%
95% CI	(9.3-11.1)	(10.1-11.9)	10.3-12.2)	(9.5-11.3)	(10.0-11.7)	(9.8-11.6)	(9.4-11.0)	(9.6-11.4)	(9.0-10.6)

Sample size, n	326	399	295	289	364	341	311	297	306
Prevalence, %	6.8%	8.6%	7.6%	7.9%	8.2%	7.7%	7.5%	8.0%	7.9%
95% CI	(5.8-7.9)	(7.5-9.7)	(6.0-8.6)	(6.7-9.0)	(7.2-9.1)	(6.7-8.6)	(6.6-8.3)	(7.0-8.9)	(6.9-8.9)
• ≥55 years									
Sample size, n	315	381	314	337	393	332	317	332	383
Prevalence, %	5.3%	6.1%	5.9%	6.2%	5.7%	4.7%	5.1%	5.6%	5.8%
95% CI	(4.5-6.0)	(5.3-7.0)	(5.2-6.7)	(5.4-7.0)	(5.0-6.4)	(4.1-5.4)	(4.4-5.7)	(4.9-6.3)	(5.1-6.4)
Females									
• ≥18 years									
Sample size, n	253	278	199	198	239	178	235	189	199
Prevalence, %	1.6%	1.5%	1.4%	1.5%	1.5%	1.5%	1.6%	1.5%	1.4%
95% CI	(1.3-1.9)	(1.2-1.7)	(1.1-1.6)	(1.3-1.8)	(1.3-1.8)	(1.2-1.7)	(1.3-1.8)	(1.1-1.8)	(1.1-1.6)
• 18-24 years									
Sample size, n	70	45	33	27	40	25	26	15	13
Prevalence, %	4.8%	2.6%	2.4%	3.0%	3.4%	3.0%	2.5%	1.9%	1.2%
95% CI	(3.3-6.2)	(1.5-3.7)	(1.4-3.4)	(1.5-4.4)	(2.1-4.7)	(1.7-4.3)	(1.5-3.6)	(0.8-3.0)	(0.4-2.0)
• 25-34 years									
Sample size, n	67	86	59	61	58	55	72	54	65
Prevalence, %	2.3%	2.8%	2.5%	2.7%	2.3%	2.9%	2.9%	2.8%	2.8%
95% CI	(1.5-3.0)	(1.9-3.7)	(1.7-3.4)	(1.9-3.6)	(1.7-3.0)	(2.0-3.8)	2.1-3.7)	(1.8-3.8)	(2.0-3.6)
• 35-54 years									
Sample size, n	83	89	64	62	95	64	85	69	79
Prevalence, %	1.4%	1.3%	1.3%	1.5%	1.7%	1.4%	1.7%	1.6%	1.8%
95% CI	(1.0-1.8)	(0.9-1.6)	(0.9-1.6)	(1.0-1.9)	(1.3-2.1)	(1.0-1.8)	(1.2-2.1)	(1.2-2.1)	(1.3-2.2)
• ≥55 years									
Sample size, n	33	58	43	48	46	34	52	51	42
Prevalence, %	0.5%	0.7%	0.6%	0.7%	0.5%	0.4%	0.7%	0.7%	0.5%
95% CI	(0.3-0.7)	(0.4-0.9)	(0.4-0.8)	(0.4-0.9)	(0.3-0.7)	(0.3-0.6)	(0.5-0.9)	(0.5-0.9)	(0.3-0.7)

*Other combustible tobacco use includes cigars, pipe tobacco, and hookah tobacco

Sample size, n	202	206	123	150	244	180	178	227	272
Prevalence, %	4.5%	4.2%	2.8%	3.4%	5.6%	4.2%	4.2%	6.3%	7.3%
95% CI	(3.7-5.3)	(3.4-5.0)	(2.2-3.5)	(2.8-4.1)	(4.8-6.4)	(3.5-5.0)	(3.5-4.8)	(5.4-7.2)	(6.3-8.4)
• ≥55 years									
Sample size, n	108	103	73	79	98	59	88	77	106
Prevalence, %	1.9%	1.5%	1.3%	1.3%	1.5%	0.9%	1.5%	1.4%	1.8%
95% CI	(1.4-2.4)	(1.1-1.9)	(1.0-1.6)	(1.0-1.7)	(1.1-1.8)	(0.6-1.2)	(1.1-1.9)	(1.1-1.7)	(1.4-2.2)
Females									
• ≥18 years									
Sample size, n	472	458	343	312	515	373	533	606	704
Prevalence, %	2.6%	2.6%	2.4%	2.3%	3.5%	2.8%	4.0%	5.2%	5.5%
95% CI	(2.3-3.0)	(2.2-2.9)	(2.0-2.7)	(2.0-2.6)	(3.1-3.9)	(2.4-3.2)	(3.6-4.4)	(4.7-5.7)	(5.0-5.9)
• 18-24 years									
Sample size, n	45	40	48	50	84	60	103	112	110
Prevalence, %	2.5%	2.3%	4.0%	4.9%	7.7%	6.5%	10.3%	13.7%	12.1%
95% CI	(1.7-3.3)	(1.4-3.1)	(2.3-5.8)	(3.3-6.6)	(5.8-9.5)	(4.5-8.6)	(8.0-12.6)	(10.9-16.6)	(9.6-14.6)
• 25-34 years									
Sample size, n	80	82	75	72	120	93	133	163	202
Prevalence, %	2.5%	3.1%	3.6%	3.2%	5.4%	4.3%	5.6%	8.4%	9.5%
95% CI	(1.7-3.3)	(2.1-4.0)	(2.6-4.6)	(2.3-4.0)	(4.3-6.6)	(3.3-5.3)	(4.5-6.6)	(7.0-9.9)	(8.1-11.0)
• 35-54 years									
Sample size, n	199	190	119	105	192	131	186	207	261
Prevalence, %	3.6%	3.5%	2.2%	2.3%	3.7%	2.8%	3.8%	5.0%	5.7%
95% CI	(3.0-4.2)	(2.8-4.2)	(1.8-2.7)	(1.8-2.8)	(3.1-4.3)	(2.2-3.4)	(3.2-4.5)	(4.2-5.8)	(4.9-6.5)
• ≥55 years									
Sample size, n	148	146	101	85	119	89	111	124	131
Prevalence, %	1.9%	1.6%	1.4%	1.1%	1.3%	1.2%	1.7%	1.6%	1.7%
95% CI	(1.7-2.3)	(1.3-2.0)	(1.1-1.8)	(0.8-1.4)	(1.1-1.6)	(0.8-1.5)	(1.3-2.1)	(1.3-1.9)	(1.4-2.0)

Sample size, n	271	316	225	245	287	226	226	192	197
Prevalence, %	5.2%	5.4%	4.7%	6.4%	5.8%	5.8%	5.9%	5.0%	5.1%
95% CI	(4.3-6.1)	(4.6-6.2)	(4.0-5.4)	(5.4-7.3)	(5.0-6.6)	(4.9-6.7)	(5.0-6.8)	(4.2-5.9)	(4.3-6.0)
• ≥55 years									
Sample size, n	130	207	137	165	185	180	179	176	202
Prevalence, %	2.6%	2.5%	2.3%	3.0%	3.0%	2.9%	2.9%	2.9%	3.0%
95% CI	(1.9-3.3)	(2.1-3.0)	(1.8-2.8)	(2.4-3.5)	(2.4-3.5)	(2.4-3.5)	(2.4-3.4)	(2.4-3.4)	(2.5-3.5)

*Oral tobacco includes chewing tobacco, moist snuff, and nicotine pouches

**The number of exclusive oral tobacco users among females was too low to reliably report prevalence estimates